The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
The common ABCG2 variant Q141K contributes to hyperuricemia and gout risk. Here, using a human interventional study and a new orthologous mouse model, the authors report a tissue specific pathobiology of the Q141K variant, and support a significant role for ABCG2 in urate excretion in both the kidne...
Guardado en:
Autores principales: | Kazi Mirajul Hoque, Eryn E. Dixon, Raychel M. Lewis, Jordyn Allan, Gregory D. Gamble, Amanda J. Phipps-Green, Victoria L. Halperin Kuhns, Anne M. Horne, Lisa K. Stamp, Tony R. Merriman, Nicola Dalbeth, Owen M. Woodward |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/12c73f6333324432b9f2c84850631506 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Philip K. Tan, et al.
Publicado: (2017) -
Management of hyperuricemia in gout: focus on febuxostat
por: Mattheus K Reinders, et al.
Publicado: (2010) -
Atypical musculoskeletal manifestations of gout in hyperuricemia patients
por: Sakti M, et al.
Publicado: (2019) -
Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population
por: Zhiqiang Li, et al.
Publicado: (2017) -
Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy
por: J. Chen, et al.
Publicado: (2021)